Video from Cambridge Biomedical’s Second Biannual Scientific Meeting – December 12, 2017

Cambridge Biomedical hosted its second annual scientific meeting this past December.  Forty scientists from the Greater Boston area attended the event focusing on the Microbiome.  It is Cambridge Biomedical’s pleasure with the approval of Synlogic to share Dr. Millet’s presentation. Once you have enjoyed the talk and would like to know how Cambridge Biomedical can contribute to your efforts please submit your request at

“Synthetic Biotic™ Medicines: A New Class of Treatments.”

Dr. Yves Millet, Synlogic Therapeutics.


The fields of synthetic biology and microbiome research have expanded greatly over the last decade enabling the development of new therapeutic strategies using engineered microbes that operate from within the gut. Synlogic is pioneering the development of a novel class of engineered, living drugs, called Synthetic Biotic™ Medicines, that can be designed to correct missing or dysfunctional metabolic activities or deliver effectors in the GI tract, with the potential to treat a wide range of diseases. The opportunities and challenges of this new therapeutic platform and the results obtained with two lead programs for the treatment of Urea Cycle Disorder and Phenylketonuria will be presented.

About Dr. Millet

Dr. Yves Millet is a Lead Scientist at Synlogic, located in Cambridge, MA, focused on the development of engineered probiotics for the treatment of rare metabolic disorders. Previously, he was a Scientist at Indigo (formerly known as Symbiota), a plant microbiome company based in Boston. Dr. Millet completed a Postdoctoral Fellowship in the laboratory of Dr. Matthew Waldor at Harvard Medical School where he studied the pathogenesis of Vibrio cholerae, the causative agent of cholera. He received his Ph.D. in Molecular and Cell Biology from Strasbourg University, France and carried out his graduate research in the laboratory of Prof. Frederick Ausubel at The Massachusetts General Hospital.